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O
R
A
L
SMethods: ADAPT-DES was a prospective, multicenter, real-world registry of 8,583
pts at 11 international centers undergoing percutaneous coronary intervention (PCI)
with DES designed to determine the frequency, timing, and correlates (clinical,
angiographic and platelet reactivity) of early and late ST. In a pre-speciﬁed IVUS
substudy, outcomes were examined according to IVUS vs. angiographic guidance. We
herein report the 2-year clinical results.
Results: Average pt age was 64.0 years, and 74.1% were male. During the index
procedure, IVUS guidance was used in 3,361 (39.2%) of procedures. Pts in the IVUS-
guided group were more likely to present with an acute coronary syndrome and have
higher platelet reactivity on clopidogrel (PRU>208), and were treated with longer and
larger stents. At 2-year follow-up, deﬁnite/probable ST occurred in 22 (0.7%) pts in
the IVUS-guidance group vs 71 (1.4%) pts in the angiography-guidance group
(P¼0.002; Table). In a propensity adjusted multivariable model, IVUS guidance was
independently associated with a reduced 2-year rate of ST (HR [95%CI] ¼ 0.43 [0.25,
0.74], p¼0.002), myocardial infarction (MI; 0.65 [0.51, 0.83], p¼0.0006), clinically
driven target lesion target revascularization (TLR; 0.77 [0.62, 0.96], p¼0.02) and
target vessel revascularization (TVR; 0.83 [0.70, 0.97], p¼0.02), and all-cause death/
MI (0.72 [0.61, 0.85], p¼0.0001).Table. 2-year outcomes according to the procedural use of IVUS
2-year event rates
IVUS group
(n=3,361)
Non-IVUS group
(n=5,221) p value
Deﬁnite/probable
ST
0.7% (22) 1.5% (71) 0.002
- Early (<30 days) 0.3% (9) 0.6% (30) 0.04
- Late (31 days - 1
year)
0.3% (10) 0.5% (24) 0.24
- Very late (1 year –
2 year)
0.15% (3) 0.45% (19) 0.01
All-cause death 3.3% (106) 4.2% (210) 0.03
Cardiac death 1.7% (54) 2.4% (119) 0.03
Myocardial
infarction
3.5% (112) 5.6% (279) <0.0001
- Peri-procedural 1.3% (44) 1.6% (84) 0.26
- Spontaneous 1.7% (52) 3.1% (151) <0.0001
- Spontaneous (<1
year)
0.8% (27) 1.7% (83) 0.001
- Spontaneous (1
year-2 year)
0.8% (25) 1.5% (68) 0.01
All-cause death/MI 6.3% (203) 9.0% (453) <0.0001
Clinically driven
TLR
4.8% (161) 6.0% (314) 0.02
Clinically driven
TVR
8.3% (279) 9.8% (510) 0.02Conclusions: These data, drawn from the largest prospective study of IVUS-guided
DES implantation to date, strongly suggest that IVUS guidance may result in
improved clinical outcomes after DES, with reduced 2-year rates of ST, TLR and
TVR, and death/MI.
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Background: The current study compared the novel Biotronik Osiro stent, eluting
sirolimus from a biodegradable polymer PLLA, applied to the surface of a thin-strut
(60 mm) Silicon-Carbide coated Cobalt-Chromium stent with the Abbot Xience
Prime stent. The aim was to compare the neointimal hyperplasia, stent appositionB22 JACC Vol 62/18/Suppl B j Ocand stent strut coverage at 9 months after procedure using IVUS and OCT imaging
techniques.
Methods: We performed a prospective, multicenter, randomized controlled study
(RCT) in 452 subjects (63.410.0 yrs) with symptomatic coronary artery disease due
to de novo stenotic lesions in native coronary arteries with a reference vessel diameter
 2.25 mm and  4.0 mm and a lesion length  26 mm. The study is registered at
clinicaltrials.gov (NCT01356888). Subjects were randomly assigned (2:1) to receive
the Osiro SES or the Xience Prime EES. In pre-speciﬁed cohort sizes, the enrolled
subjects were invited to participate in either the IVUS (N¼66) or the OCT (N¼65) sub
studies. All subjects were enrolled between July 5, 2011 - Jan 10, 2012. The IVUS
endpoints were neointimal hyperplasia and stent apposition at 9 months after proce-
dure. The OCT endpoints were neointimal hyperplasia, stent apposition and stent strut
coverage at 9 months. Baseline and 9 month follow-up images were analyzed by
independent and blinded core laboratories; IVUS by Medstar, US and OCT by Car-
dialysis, NL.
Results: IVUS and OCT conﬁrmed complete and a non-signiﬁcant difference in
apposition in both cohorts (OCT P¼0.624 and IVUS P¼0.325). IVUS and OCT
conﬁrmed less neointimal hyperplasia area at 9-months in the Osiro cohort (OCT
P¼0.024 and IVUS P¼0.043). The Osiro cohort had a higher strut coverage and lower
strut-neointima thickness at 9 months, conﬁrmed by OCT (coverage P¼0.042 and
thickness P<0.001).
Conclusions: In this RCT, the Osiro SES with a biodegradable polymer showed
comparable stent and strut apposition to the Xience Prime EES with a durable
polymer. The Osiro had a statistically signiﬁcant lower neointimal area in both the
IVUS and OCT sub studies. OCT analysis of the strut level conﬁrmed that both the
neointima thickness and percent coverage was signiﬁcantly better in the Osiro cohort.
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Background: The objective of this study is to examine the phenotypic changes of the
superﬁcial plaque occurring follow an Absorb bioresorbable vascular scaffold (Absorb
BVS) implantation.
Methods: Forty six patients (47 lesions) who underwent Absorb BVS implantation
and had serial optical coherence tomographic evaluation at baseline, and at any
follow-up time point (6 months, 1 year, 2 years or 3 years) were included in the
current analysis. Two observers identiﬁed thin capped ﬁbroatheromas (TCFA) in the
scaffolded and native segments that were located proximally or distally to the scaf-
folded segment, marked the circumferential location of the TCFA and of the calciﬁc
tissues and measured the thickness of the developed neointima at follow-up. These
data were used to construct spread-out vessel plots that portrayed the spatial location
of the detected tissues and their extent was expressed as percentage of the endoluminal
vessel wall surface.
Results: Twelve TCFA were detected at baseline in the scaffolded segments and all
were covered at follow-up. On the other hand most of the TCFA identiﬁed in native
segments (6 out of 10) did not change their phenotype at follow-up. The amount of the
superﬁcial lipid core remained unchanged at follow-up in the spread-out vessel plots
in both the scaffolded (4.9010.12% at baseline vs. 4.1810.84%, at follow-up,
P¼0.388) and native segments (28.4720.87% at baseline vs. 28.1222.00%, at
follow-up, P¼0.767). There was no difference in the thickness of the neointima
developed over TCFA and calciﬁc spots in scaffolded segments at follow-up (mean
thickness over TCFA: 22383mm vs. 21388mm over calciﬁc spots, P¼0.687).
Conclusions: Our results demonstrate that the neointimal tissue developed after
Absorb BVS implantation shields equally both lipid and calciﬁc tissues. Thus, the
Absorb BVS could be considered as a potential useful device for the invasive re-
capping of high risk plaques.
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Background: The morphological assessment of neointimal tissue using optical
coherence tomography (OCT) is highly signiﬁcant to clarify the pathophysiology of
in-stent restenosis (ISR) lesions. These OCT ﬁndings may be related to recurrence of
ISR. The aim of this study was to deﬁne the impact of OCT ﬁndings on recurrence
of ISR after various types of percutaneous coronary intervention (PCI) including plaintober 27–November 1, 2013 j TCT Abstracts/ORAL/Invasive Imaging
